Evaluating the Results of Physician and Parent Decisions to Treat Selective Mutism With Fluoxetine

• Status: Completed
• Trial end date: 2015-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The Department of Counseling, Educational Psychology, and Special Education and the Department of Psychiatry at Michigan State University have coordinated efforts to provide a diagnostic and treatment investigation for children, ages seven to eighteen, with Selective Mutism. The purpose of this study is to examine the utility of fluoxetine for the treatment of this debilitating disorder. Fluoxetine is expected to improve social anxiety and selective mutism symptomology.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michigan State University
• Treatments: Fluoxetine

Criteria

Inclusion Criteria:

• Male or female from seven to seventeen years of age at their last birthday

• Meet DSM-IV-TR criteria for selective mutism

• No history of medication treatment for selective mutism

• Child has an immediate biological family member who is diagnosed with an anxiety disorder or has experienced symptoms of an anxiety disorder at some point in time

• Child has received 10 weeks of an evidence-based psychosocial treatment

• Child has never had a negative reaction to a psychopharmacological medication

• Child exhibits symptoms of social anxiety

Exclusion Criteria:

• Child is diagnosed with a speech condition, mental retardation, pervasive developmental disorder, or schizophrenia

• Child is an English language learner or from a different culture than the culture predominately represented within his or her school

• Child is taking or has taken any kind of a psychopharmacological medication (e.g., SSRI, MAO-I, stimulant, etc.)

• Child has a medical illness that may be complicated through the use of a psychopharmacological treatment